AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
189.76
+2.30 (1.23%)
May 21, 2026, 4:00 PM EDT - Market closed
AstraZeneca Employees
AstraZeneca had 95,100 employees as of December 31, 2025. The number of employees increased by 2,200 or 2.37% compared to the previous year.
Employees
95,100
Change (1Y)
2,200
Growth (1Y)
2.37%
Revenue / Employee
$635,531
Profits / Employee
$109,243
Market Cap
291.18B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 95,100 | 2,200 | 2.37% |
| Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
| Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
| Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
| Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
| Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
| Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
| Dec 31, 2013 | 51,500 | -200 | -0.39% |
| Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
| Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
| Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
| Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
| Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
| Dec 31, 2007 | 67,400 | 600 | 0.90% |
| Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
| Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
| Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
| Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
| Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
AZN News
- 1 day ago - AstraZeneca designates key managerial personnel for materiality determination - Business Upturn
- 1 day ago - Top 5 FTSE 100 AI Stocks to Watch in 2026: Exposure Across Pharma, Defense and Infrastructure - International Business Times (Australia)
- 3 days ago - AstraZeneca (AZN) Faces Potential Market Shifts Amid Trump's Prescription Plan - GuruFocus
- 3 days ago - AstraZeneca (AZN) Secures FDA Approval for Groundbreaking Treatment - GuruFocus
- 3 days ago - US Supreme Court rebuffs pharma challenge to Biden-era drug price - Reuters
- 3 days ago - Jefferies says Baxfendy approval may be incrementally constructive for Mineralys - TheFly
- 3 days ago - The Zacks Analyst Blog Highlights Costco, Coca-Cola, AstraZeneca and Franklin Financial Services - Nasdaq
- 3 days ago - AstraZeneca (AZN) Receives US Approval for Innovative Hypertension Treatment - GuruFocus